24H | INmune Bio Soars 70% as It to Present Phase 2 Trial Data; BigBear.ai Jumps 5% After a 20% Rally in Prior Session

Tiger Newspress
27 Jun

INmune Bio shares jumped nearly 70% in overnight trading after the company said it would report top-line data from an Alzheimer's disease drug trial on Monday.

The Boca Raton, Fla., company said it would present data for its XPro drug candidate from the Phase 2 MINDFuL trial in a conference call set for 8:00 a.m. ET on Monday. The trial includes patients with mild cognitive impairment or Alzheimer's disease with brain inflammation.

INmune previously said the primary endpoint is a change from baseline in cognitive scores measured with the Early and Mild Alzheimer's Cognitive Composite.

BigBear.ai rose 4.8% in overnight trdaing after a 20% rally in prior session.

BigBear.ai, a provider of AI solutions focused on national security, offers a high-risk, high-reward investment opportunity. While the company enjoys notable contract victories and a strong position in the defense industry, it is also hindered by ongoing financial difficulties and significant stock price fluctuations.

Despite its promising market, the financial path of BBAI shows troubling stagnation. BigBear.ai's Revenue in 2024 reached $158 million, marking a mere 2% rise from $155 million in 2023.

In spite of its financial challenges, BigBear.ai has several notable positive factors:

  • Growing Backlog: The company’s backlog increased 2.5 times from $168 million at the end of 2023 to $385 million by the end of March 2025. This significant rise offers essential revenue visibility, even amid execution difficulties.

  • Key Government Contracts: BBAI has secured multiple major government contracts in 2025, including a 3.5-year, $13.2 million sole-source Department of Defense (DoD) contract to upgrade a vital force management system.

  • Strategic Market Position: BigBear.ai operates in crucial AI applications related to national security, developing solutions such as facial recognition systems for airports and AI-augmented shipbuilding software for the U.S. Navy. The current elevated geopolitical climate strongly favors increased defense AI investments, generating a supportive market environment for the company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10